Abstract
Rationale
Positive allosteric modulators (PAMs) of type 5 metabotropic glutamate receptors (mGluR5) exert pro-cognitive effects in animal models of various neuropsychiatric diseases. However, few studies to date have examined ability of mGluR5 PAMs to reverse cognitive deficits in operant delayed matching/non-matching-to-sample (DMS/DNMS) tasks.
Objectives
This study aims to determine the ability of the mGluR5 PAM 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) to reverse set-shifting deficits induced by the N-methyl-d-aspartate (NMDA) receptor antagonist MK-801.
Methods
Male Sprague-Dawley rats were initially trained to lever press for sucrose reinforcement under either DMS or DNMS conditions. Following successful acquisition of the task, reinforcement conditions were reversed (DNMS → DMS or DMS → DNMS). In Experiment 1, rats were treated daily prior to each session with vehicle/vehicle, vehicle/MK-801 (0.06 mg/kg) simultaneously, CDPPB (20 mg/kg)/MK-801 simultaneously, or CDPPB 30 min prior to MK-801. In Experiment 2, rats were treated with either vehicle/vehicle, vehicle/MK-801, or CDPPB 30 min prior to MK-801 only prior to sessions that followed task reversal.
Results
In Experiment 1, no group differences in initial task acquisition were observed. Rats treated with vehicle/MK-801 showed significant set-shifting impairments following task reversal, which were partially attenuated by simultaneous administration of CDPPB/MK-801 and completely precluded by administration of CDPPB 30 min prior to MK-801. In Experiment 2, MK-801 did not impair reversal learning, and no other group differences were observed.
Conclusions
MK-801-induced deficits in operant set-shifting ability were prevented by pretreatment with CDPPB. MK-801 did not produce deficits in task learning when treatment was initiated following task reversal.
Similar content being viewed by others
References
Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R, Telk AN, Watson NL, Xiang Z, Zhang Y, Jones PJ, Lindsley CW, Olive MF, Conn PJ (2009) mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 34:2057–2071
Balschun D, Zuschratter W, Wetzel W (2006) Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 142:691–702
Braff DL, Heaton R, Kuck J, Cullum M, Moranville J, Grant I, Zisook S (1991) The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry 48:891–898
Burns GA, Ritter RC (1997) The non-competitive NMDA antagonist MK-801 increases food intake in rats. Pharmacol Biochem Behav 56:145–149
Chadman KK, Watson DJ, Stanton ME (2006) NMDA receptor antagonism impairs reversal learning in developing rats. Behav Neurosci 120:1071–1083
Chen Y, Conn PJ (2008) mGluR5 positive allosteric modulators. Drugs Future 33:355–360
Clifton NE, Morisot N, Girardon S, Millan MJ, Louseau F (2013) Enhancement of social novelty discriminationby positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology 225:579–594
Darrah JM, Stefani MR, Moghaddam B (2008) Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol 19:225–234
Dudchenko PA (2004) An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev 28:699–709
Dudchenko PA, Talpos J, Young J, Baxter MG (2013) Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. Neurosci Biobehav Rev 37:2111–2124
Egerton A, Reid L, McKerchar CE, Morris BJ, Prat JA (2005) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 179:77–84
Fowler SW, Ramsey AK, Walker JM, Serfozo P, Olive MF, Schachtman TR, Simonyi A (2011) Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats. Neurobiol Learn Mem 95:73–79
Fowler SW, Walker JM, Klakotskaia D, Will MJ, Serfozo P, Simonyi A, Schachtman TR (2013) Effects of a metabotropic glutamate receptor 5 positive allosteric modulator, CDPPB, on spatial learning task performance in rodents. Neurobiol Learn Mem 99:25–31
Franke P, Maier W, Hain C, Klingler T (1992) Wisconsin Card Sorting Test: an indicator of vulnerability to schizophrenia? Schizophr Res 6:243–249
Gastambide F, Cotel MC, Gilmour G, O'Neill MJ, Robbins TW, Tricklebank MD (2012) Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 37:1057–1066
Gastambide F, Gilmour G, Robbins TW, Tricklebank MD (2013) The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology 64:240–247
Gerber U, Gee CE, Benquet P (2007) Metabotropic glutamate receptors: intracellular signaling pathways. Curr Opin Pharmacol 7:56–61
Gillespie BR, Burns GA, Ritter RC (2005) NMDA channels control meal size via central vagal afferent terminals. Am J Physiol Regul Integr Comp Physiol 289:R1504–R1511
Gilmour G, Broad LM, Wafford KA, Britton T, Colvin EM, Fivush A, Gastambide F, Getman B, Heinz BA, McCarthy AP, Prieto L, Shanks E, Smith JW, Taboada L, Edgar DM, Tricklebank MD (2013) In vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology 64:224–239
Goldberg TE, Weinberger DR, Berman KF, Pliskin MA, Podd MH (1987) Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 44:1008–1014
Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41–51
Hagan JJ, Jones DN (2005) Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 31:830–853
Harder JA, Aboobaker AA, Hodgetts TC, Ridley RM (1998) Learning impairments induced by glutamate blockade using dizocilpine (MK-801) in monkeys. Br J Pharmacol 125:1013–1018
Hermans E, Challiss RA (2001) Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem J 359:465–484
Homayoun H, Moghaddam B (2008) Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc Natl Acad Sci U S A 105:18041–18046
Homayoun H, Moghaddam B (2010) Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition. Eur J Pharmacol 639:33–39
Horio M, Fujita Y, Hashimoto K (2013) Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundam Clin Pharmacol 27:483–488
Javitt DC (2012) Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol 213:367–399
Joel D, Weiner I, Feldon J (1997) Electrolytic lesions of the medial prefrontal cortex in rats disrupt performance on an analog of the Wisconsin Card Sorting Test, but do not disrupt latent inhibition: implications for animal models of schizophrenia. Behav Brain Res 85:187–201
Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199–206
Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS (2010) Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24:669–693
Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B (2007) Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 62:739–746
Li JT, Su YA, Guo CM, Feng Y, Yang Y, Huang RH, Si TM (2011) Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats. Eur J Pharmacol 652:65–72
Lin CH, Lane HY, Tsai GE (2012) Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 100:665–77
Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA (2013) Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem 13:26–54
Murray TK, Ridley RM, Snape MF, Cross AJ (1995) The effect of dizocilpine (MK-801) on spatial and visual discrimination tasks in the rat. Behav Pharmacol 6:540–549
Niswender CM, Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295–322
Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523–533
Palencia CA, Ragozzino ME (2004) The influence of NMDA receptors in the dorsomedial striatum on response reversal learning. Neurobiol Learn Mem 82:81–89
Parmentier-Batteur S, Hutson PH, Menzel K, Uslaner JM, Mattson BA, O'Brien JA, Magliaro BC, Forest T, Stump CA, Tynebor RM, Anthony NJ, Tucker TJ, Zhang XF, Gomez R, Huszar SL, Lambeng N, Faure H, Le Poul E, Poli S, Rosahl TW, Rocher JP, Hargreaves R, Williams TM (2014) Mechanism based neurotoxicity of mGlu5 positive allosteric modulators—development challenges for a promising novel antipsychotic target. Neuropharmacology 82:161–173
Piers TM, Kim DH, Kim BC, Regan P, Whitcomb DJ, Cho K (2012) Translational concepts of mGluR5 in synaptic diseases of the brain. Front Pharmacol 3:199
Reichel CM, Schwendt M, McGinty JF, Olive MF, See RE (2011) Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 36:782–792
Rowley M, Bristow L, Hutson P (2001) Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 44:477–501
Silver H, Feldman P, Bilker W, Gur RC (2003) Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 160:1809–1816
Snyder MA, Gao WJ (2013) NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci 7:31
Stefani MR, Moghaddam B (2010) Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur J Pharmacol 639:26–32
Treece BR, Ritter RC, Burns GA (2000) Lesions of the dorsal vagal complex abolish increases in meal size induced by NMDA receptor blockade. Brain Res 872:37–43
Uslaner JM, Parmentier-Batteur S, Flick RB, Surles NO, Lam JS, McNaughton CH, Jacobson MA, Hutson PH (2009) Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 57:531–538
Vales K, Svoboda J, Benkovicova K, Bubenikova-Valesova V, Stuchlik A (2010) The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801. Eur J Pharmacol 639:91–98
van der Meulen JA, Bilbija L, Joosten RN, de Bruin JP, Feenstra MG (2003) The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats. Neuroreport 14:2225–2228
van der Staay FJ, Rutten K, Erb C, Blokland A (2011) Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behav Brain Res 220:215–229
Vandenberg RJ, Aubrey KR (2001) Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin Ther Targets 5:507–518
Vardigan JD, Huszar SL, McNaughton CH, Hutson PH, Uslaner JM (2010) MK-801 produces a deficit in sucrose preference that is reversed by clozapine, Lu-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol Biochem Behav 95:223–229
Varvel SA, Vann RE, Wise LE, Philibin SD, Porter JH (2002) Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology 160:182–191
Vezzani A, Serafini R, Stasi MA, Caccia S, Conti I, Tridico RV, Samanin R (1989) Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J Pharmacol Exp Ther 249:278–283
Wozniak DF, Olney JW, Kettinger L, Price M, Miller JP (1990) Behavioral effects of MK-801 in the rat. Psychopharmacology 101:47–56
Zhang Y, Rodriguez AL, Conn PJ (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 315:1212–1219
Zito K, Scheuss V (2009) NMDA receptor function and physiological modulation. In: Squire LR (ed) Encyclopedia of Neuroscience. Academic Press, Oxford, pp 1157–1164
Acknowledgments
This work was funded by NIH grant DA024355 to MFO.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
LaCrosse, A.L., Burrows, B.T., Angulo, R.M. et al. mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching/non-matching-to-sample task. Psychopharmacology 232, 251–258 (2015). https://doi.org/10.1007/s00213-014-3653-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-014-3653-8